Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology
company, today announced that its Chief Scientific Officer Prof. Cornelis
Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in
Vancouver, BC, Canada, January 20-24, 2019.
The talk titled
“Therapeutic HPV16 Vaccination Is Effective as Monotherapy in
Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced
Cancers” is scheduled for Thursday, January 24, 2019, at 17:00 as part of the
session “Immune Monitoring of T Cells” (17:00-18-45, Pacific Ballroom).
The data will
outline the T cell response to ISA Pharmaceuticals´ therapeutic vaccine ISA101 and
the resulting clinical activity. ISA101 is directed against the HPV16 oncoproteins
E6/E7 and is the Company´s clinical-stage lead compound. It is being developed
to treat HPV16-induced cancers such as cervical cancer and head-and-neck cancer.
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is
an immunotherapy company developing rationally designed, fully synthetic
immunotherapeutics against cancer and persistent viral infections. The company
has built a proprietary immunotherapy platform based on the Synthetic Long
Peptide (SLP®) concept and AMPLIVANT® technology. SLP®
immunotherapies are designed to fully harness and direct the body’s own
defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals
closed a clinical immuno-oncology collaboration with Regeneron to advance its
SLP® lead compound ISA101, an immunotherapy targeting human
papillomavirus type 16 (HPV16)-induced cancer, in combination with Cemiplimab
(REGN2810), a PD-1 (programmed cell death protein 1) antibody. In addition, ISA
develops SLP® immunotherapies to advance novel treatment options for
For more information,
please visit www.isa-pharma.com.
SLP® and AMPLIVANT® are
registered trademarks in Europe.